Skip to content

Epidemiological Study on Community Acquired Pneumonia

Epidemiological Study on Community Acquired Pneumonia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02139163
Acronym
CAPNETZ
Enrollment
20000
Registered
2014-05-15
Start date
2002-10-01
Completion date
2028-06-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community Acquired Pneumonia

Keywords

Community acquired pneumonia, CAP, CAPNETZ, age ≥18, infiltrate on chest X-ray, cough or production of purulent sputum, pathologic lung auscultation, fever, adults

Brief summary

The main objective of this study is to investigate prevalence and risk factors for community-acquired pneumonia (CAP) and its interaction with comorbidities in an unselected group of adult patients receiving outpatient and inpatient care. In addition, information on HIV as a risk factor for CAP and on CAP in immunocompromised patients is collected.

Detailed description

The CAPNETZ study is a prospective, multicenter observational study investigating community-acquired pneumonia (CAP). Patients are recruited from outpatient and inpatient settings at hospitals and from primary care physicians (primarily specialists) and are followed for a period of six months. All CAP patients who meet the inclusion and exclusion criteria, consent to participate, and in whom the presence of a newly developed, community-acquired pneumonia can be verified are invited to participate. The baseline examination includes a detailed medical history, medication history, and a physical examination to record clinical and vital signs. In addition, the results of routine clinical imaging are documented, and biosamples (blood, urine, and respiratory specimens) are collected for clinical chemistry and microbiological analysis. Further in-person visits to document the course of the disease and treatment, including the collection of additional blood samples, take place 3 and 7 days after study enrollment. Twenty-eight days after enrollment, the patient's health status, treatment course, and complications are assessed by telephone. Finally, after 180 days, a telephone survey is conducted to determine the patient's whereabouts and survival status. Apart from the collection of biomaterials, no interventions are required or planned; physicians treat their patients as they normally would.

Interventions

None listed

Sponsors

Capnetz Stiftung
Lead SponsorOTHER
Deutsches Zentrum für Lungenforschung e. V.
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥ 18 * infiltrate on chest X-ray * further Inclusion criteria (at least one must apply): cough or purulent sputum or pathologic lung auscultation (crackles) or fever

Exclusion criteria

* Hospitalization lasting longer than 48 hours prior to the diagnosis of the current pneumonia * Newly diagnosed, active pulmonary tuberculosis within the last 2 months

Design outcomes

Primary

MeasureTime frameDescription
diagnosis2 weeksAssessment of diagnosis: Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms.
therapy2 weeksAssessment of therapy: Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc.
hospitalization2 weeksAssessment of hospitalization: Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms.

Countries

Germany

Contacts

CONTACTFrank Eberhardt
office@capnetz.de+49-511-532-5927
CONTACTWaldemar Kröner
office@capnetz.de+49-511-532-4447
STUDY_CHAIRGernot G. U. Rohde, Prof. Dr.

University Hospital Giessen and Marburg

STUDY_CHAIRMathias W. R. Pletz, Prof. Dr.

University Hospital Jena

STUDY_CHAIRJan Rupp, Prof. Dr.

University Hospital Schleswig-Holstein

STUDY_CHAIRMartin Witzenrath, Prof. Dr.

Charité - Universitaetsmedizin Berlin

STUDY_CHAIRJessica Rademacher, Prof. Dr.

Medical School Hannover

STUDY_CHAIRGrit Barten-Neiner

Capnetz Stiftung

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026